

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**Equality and health inequality impact assessment**

**Sotorasib for previously treated KRAS  
G12C mutation-positive advanced non-  
small-cell lung cancer (Managed Access  
review of TA781) [ID6287]**

**Final draft guidance (when issued)**

- 1 Have any additional potential equality or health inequality issues been raised during consultation on the draft guidance? If so, how has the committee addressed these?**

A patient organisation highlighted that inconsistent KRAS testing may already create inequalities in access to targeted treatments. It noted that removing access to sotorasib would risk worsening this inequality by limiting options, even when a KRAS mutation is identified. The patient organisation also highlighted that even if recommendations apply equally to all people, its impact is not experienced equally.

- 2 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

No

- 3 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

No, the recommendations have not changed after consultation.

- 4 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments in the recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE’s obligations to promote equality.**

No, the recommendations have not changed after consultation.

- 5 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?**

Yes. The committee considered whether any of the issues raised were health inequality issues. It noted that although the concerns raised by the patient organisation were plausible, no robust qualitative or quantitative evidence had been provided to demonstrate that this evaluation would directly worsen or address any health inequalities. So, it could not consider how potential health inequalities could impact its decision making and could not accept a higher level of uncertainty.

- 6 Have the committee’s considerations of equality and health inequality issues been described in the final draft guidance? If so, where?**

Yes, in section 3.23.

**Approved by senior responsible officer:** Ross Dent

**Date:** 11/06/2026